Acute and repeated dose (28 days) toxicity studies in rats and dogs of recombinant batroxobin, a snake venom thrombin-like enzyme expressed from Pichia pastoris

State-of-the-art review - A review on snake venom-derived antithrombotics: Potential therapeutics for COVID-19-associated thrombosis?

“…A subsequent study has shown that rCollinein-1 may have therapeutic potential in preventing thrombus formation [149] . An acute and repeated dose (28 days) toxicity study of a recombinant thrombin-like defibrinogenating enzyme, batroxobin expressed in Pichia pastoris , showed no adverse effects at a dose of 2.5 NIH u/kg in rats and 1 NIH u/kg in dogs, indicating clinical potential in the treatment of hemostatic disturbances [150] . In another approach, a novel thrombin-like enzyme with fibrinogenolytic activity from Deinagkistrodon acutus venom was expressed in soluble form in E. coli .…”